The grant is funded through the U.S. Department of Defense’s Breast Cancer Research Program and Breakthrough Award. It will fund the second phase of Mayo’s clinical trial, which will enroll 280 patients across the country and test the ability of a folate receptor alpha vaccine to prevent recurrence of triple-negative breast cancer following initial treatment.
The folate receptor alpha vaccine was designed by the grant’s principal investigator, Keith Knutson, PhD, and was initially tested by researchers at Mayo Clinic’s Rochester campus for safety and efficacy.
The newly funded trial is scheduled to begin in early 2016.
More articles on breast cancer:
Up to 17M women could lose mammogram coverage
IBM Watson partners with 14 cancer centers to identify personalized treatments
$4B: The annual national cost for false-positive mammograms and breast cancer overdiagnoses
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.